1. Home
  2. DRD vs TRVI Comparison

DRD vs TRVI Comparison

Compare DRD & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DRDGOLD Limited

DRD

DRDGOLD Limited

HOLD

Current Price

$26.72

Market Cap

2.5B

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$16.07

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DRD
TRVI
Founded
1895
2011
Country
South Africa
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.6B
IPO Year
2002
2019

Fundamental Metrics

Financial Performance
Metric
DRD
TRVI
Price
$26.72
$16.07
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
11
Target Price
$32.63
$21.55
AVG Volume (30 Days)
281.4K
1.3M
Earning Date
08-19-2026
05-05-2026
Dividend Yield
2.24%
N/A
EPS Growth
N/A
31.91
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$39.23
N/A
Revenue Next Year
$30.12
N/A
P/E Ratio
$15.32
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.47
$7.65
52 Week High
$39.37
$20.22

Technical Indicators

Market Signals
Indicator
DRD
TRVI
Relative Strength Index (RSI) 51.18 33.27
Support Level $26.37 $13.08
Resistance Level $27.25 $15.96
Average True Range (ATR) 0.84 0.72
MACD -0.39 -0.17
Stochastic Oscillator 2.28 3.82

Price Performance

Historical Comparison
DRD
TRVI

About DRD DRDGOLD Limited

DRDGold Ltd is a South African gold mining company engaged in surface gold tailings retreatment including exploration, extraction, processing, and smelting. Its reportable operating segments are; Ergo, FWGR, and Corporate office and other reconciling items. The Ergo is a surface gold retreatment operation that treats old slime dams and sand dumps to the south of Johannesburg's central business district as well as the East and Central Rand goldfields, and the FWGR which is a surface gold retreatment operation and treats old slime dams in the West Rand goldfields. The Ergo segment derives a vast majority of the company's revenue.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: